KRAS mutations detected by the amplification refractory mutation system–Scorpion assays strongly correlate with therapeutic effect of cetuximab
Open Access
- 5 July 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 105 (3), 403-406
- https://doi.org/10.1038/bjc.2011.247
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Biased Discordance of KRAS Mutation Detection in Archived Colorectal Cancer Specimens Between the ARMS-Scorpion Method and Direct SequencingJapanese Journal of Clinical Oncology, 2010
- Feasibility and Robustness of Amplification Refractory Mutation System (ARMS)-based KRAS Testing Using Clinically Available Formalin-fixed, Paraffin-embedded Samples of Colorectal CancersJapanese Journal of Clinical Oncology, 2010
- A Commercial Real-Time PCR Kit Provides Greater Sensitivity than Direct Sequencing to Detect KRAS Mutations: A Morphology-Based Approach in Colorectal CarcinomaThe Journal of Molecular Diagnostics, 2010
- Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding MetastasesClinical Cancer Research, 2010
- KRAS Mutation: Comparison of Testing Methods and Tissue Sampling Techniques in Colon CancerThe Journal of Molecular Diagnostics, 2010
- Targeted KRAS Mutation Assessment on Patient Tumor Histologic Material in Real Time DiagnosticsPLOS ONE, 2009
- American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody TherapyJournal of Clinical Oncology, 2009
- KRAS Mutations and Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer: Practical Application of Patient SelectionJournal of Clinical Oncology, 2009
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal CancerNew England Journal of Medicine, 2008
- Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2008